Pharmacovigilance – News and Features

Phase II study of nimotuzumab in pediatric patients with recurrent diffuse intrinsic pontine glioma.

NIH stops one treatment arm of trial, other two treatments to continue.

The company has identified a molecule highly active in inhibiting the intestinal absorption of lipids, making it an excellent candidate for fighting dyslipidemia and associated cardiac events.

NIH-supported group exploring whether protection extends to Nipah virus disease.

Catherine A. Tyner joins the company as executive director, oversight group management to augment Novella’s service offerings.

Protein could be a target for treating people who have the blood disorder.

Data from trial published in journal of clinical oncology.

Clinical proof-of-principle achieved, Company to begin phase 2b trial in 2012.

BioCryst Pharmaceuticals, Inc. announces positive top-line results from its Phase 2b randomized, double-blind, dose-response study of BCX4208 in gout patients.

First presentation of full ALSYMPCA phase III data as part of Presidential Session featuring Best and Late-Breaking Abstracts at 2011 EMCC.